This is a continuation application from the Atlanta Regional Community Clinical Oncology Program (ARCCOP) which was first funded in 1987. The ARCCOP has grown to a consortium of six hospitals (one component and five affiliate institutions) that almost completely surround the Atlanta metropolitan area. Over the past six years, 414 patients have been enrolled in clinical trials, and 149 in cancer control studies. The ARCCOP has been successful in accomplishing the specific aims developed for the last proposal: coordinate and expand existing hospital resources; meet/surpass clinical trial accrual; meet/surpass cancer control protocol accrual; collaborate with the three research bases (SWOG, NSABP, MDACC); refine the data management system; expand the quality assurance program; maintain investigator standards; increase the involvement of primary care physicians; and involve other regional institutions and physicians in clinical trials. Plans for the next funding cycle include continuation of these goals as well as disseminating research outcomes to ARCCOP health care professionals, increasing the number of minority patients on clinical and cancer control studies, and implementation of an active marketing plan. In 1992, the ARCCOP was designated as a clinical site for the Breast Cancer Prevention Trial, and more recently, the Prostate Cancer Prevention Trial, further attesting to the experience of the investigators and the leadership and organizational skill of the key personnel. Quality assurance mechanisms have been proven effective by successful research base audits. Renewed funding will allow this outstanding research program to continue to assist the NCI in reducing cancer incidence, morbidity, and mortality by assisting the transfer of new technologies to widespread community application.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045450-12
Application #
2712612
Study Section
Special Emphasis Panel (SRC (74))
Project Start
1987-08-01
Project End
1999-05-31
Budget Start
1998-06-26
Budget End
1999-05-31
Support Year
12
Fiscal Year
1998
Total Cost
Indirect Cost
Name
St. Joseph's Hospital
Department
Type
DUNS #
City
Atlanta
State
GA
Country
United States
Zip Code
30342
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Friedberg, Jonathan W; Unger, Joseph M; Burack, W Richard et al. (2014) R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. Br J Haematol 166:382-9
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33

Showing the most recent 10 out of 52 publications